Synergy Pharmaceuticals Inc. (SGYP) Sees Strong Trading Volume
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) shares saw unusually-strong trading volume on Monday . Approximately 4,150,568 shares were traded during trading, an increase of 68% from the previous session’s volume of 2,469,988 shares.The stock last traded at $5.05 and had previously closed at $4.99.
Several equities research analysts recently commented on SGYP shares. Rodman & Renshaw reaffirmed a “buy” rating and set a $16.00 target price on shares of Synergy Pharmaceuticals in a research note on Thursday, April 21st. Roth Capital reaffirmed a “buy” rating on shares of Synergy Pharmaceuticals in a research note on Monday, May 9th. BTIG Research reaffirmed a “buy” rating and set a $11.00 target price on shares of Synergy Pharmaceuticals in a research note on Tuesday, April 19th. Canaccord Genuity reaffirmed a “buy” rating and set a $13.00 target price on shares of Synergy Pharmaceuticals in a research note on Monday, May 23rd. Finally, Zacks Investment Research raised Synergy Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Monday, May 16th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $10.37.
The stock’s 50-day moving average is $4.15 and its 200 day moving average is $3.57. The company’s market cap is $915.17 million.
Synergy Pharmaceuticals (NASDAQ:SGYP) last released its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by $0.03. Equities analysts forecast that Synergy Pharmaceuticals Inc. will post ($1.05) EPS for the current year.
Synergy Pharmaceuticals Inc (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.